Company Presentation

Phase 3 stage Company developing therapies for the treatment of IL-18 mediated systemic hyper-inflammatory disorders with high unmet medical need. Tadekinig alfa, the recombinant version of physiological human IL-18 Binding Protein, will treat the underlaying disease mechanisms by restoring IL-18 homeostasis. First BLA submission planned for 2023 in monogenic primary HLH. PoC and PoC ready in Still’s Disease, HSCT and MAS-like syndromes / CRS associated with CAR-T.